Isis Pharmaceuticals said today that its diagnostic subsidiary, Ibis Biosciences, was awarded federal grants and contracts worth as much as $8.4 million. The Carlsbad, CA-based company (NASDAQ: [[ticker:ISIS]]) said its subsidiary got the grants and contracts from the U.S. Department of Agriculture, National Institute of Justice, and other agencies. The company is being asked to help identify flu viruses, other pathogens, and offer improved forensics.
Author: Luke Timmerman
Luke is an award-winning journalist specializing in life sciences. He has served as national biotechnology editor for Xconomy and national biotechnology reporter for Bloomberg News. Luke got started covering life sciences at The Seattle Times, where he was the lead reporter on an investigation of doctors who leaked confidential information about clinical trials to investors. The story won the Scripps Howard National Journalism Award and several other national prizes. Luke holds a bachelor’s degree in journalism from the University of Wisconsin-Madison, and during the 2005-2006 academic year, he was a Knight Science Journalism Fellow at MIT.
View all posts by Luke Timmerman
